Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 375

1.

Pace of movement: the role of single neurons in the subthalamic nucleus.

Tankus A, Mirelman A, Giladi N, Fried I, Hausdorff JM.

J Neurosurg. 2018 Jun 22:1-6. doi: 10.3171/2018.1.JNS171859. [Epub ahead of print]

PMID:
29932375
2.

SPARC: a new approach to quantifying gait smoothness in patients with Parkinson's disease.

Beck Y, Herman T, Brozgol M, Giladi N, Mirelman A, Hausdorff JM.

J Neuroeng Rehabil. 2018 Jun 18;15(1):49. doi: 10.1186/s12984-018-0398-3.

3.

Consensus for the measurement of the camptocormia angle in the standing patient.

Margraf NG, Wolke R, Granert O, Berardelli A, Bloem BR, Djaldetti R, Espay AJ, Fasano A, Furusawa Y, Giladi N, Hallett M, Jankovic J, Murata M, Tinazzi M, Volkmann J, Berg D, Deuschl G.

Parkinsonism Relat Disord. 2018 Jun 8. pii: S1353-8020(18)30272-4. doi: 10.1016/j.parkreldis.2018.06.013. [Epub ahead of print]

PMID:
29907329
4.

Cerebral Imaging Markers of GBA and LRRK2 Related Parkinson's Disease and Their First-Degree Unaffected Relatives.

Thaler A, Kliper E, Maidan I, Herman T, Rosenberg-Katz K, Bregman N, Gurevich T, Shiner T, Hausdorff JM, Orr-Urtreger A, Giladi N, Mirelman A.

Brain Topogr. 2018 May 30. doi: 10.1007/s10548-018-0653-8. [Epub ahead of print]

PMID:
29846835
5.

Parkinson's disease phenotype is influenced by the severity of the mutations in the GBA gene.

Thaler A, Bregman N, Gurevich T, Shiner T, Dror Y, Zmira O, Gan-Or Z, Bar-Shira A, Gana-Weisz M, Orr-Urtreger A, Giladi N, Mirelman A.

Parkinsonism Relat Disord. 2018 May 17. pii: S1353-8020(18)30239-6. doi: 10.1016/j.parkreldis.2018.05.009. [Epub ahead of print]

PMID:
29784561
6.

Model-based and Model-free Machine Learning Techniques for Diagnostic Prediction and Classification of Clinical Outcomes in Parkinson's Disease.

Gao C, Sun H, Wang T, Tang M, Bohnen NI, Müller MLTM, Herman T, Giladi N, Kalinin A, Spino C, Dauer W, Hausdorff JM, Dinov ID.

Sci Rep. 2018 May 8;8(1):7129. doi: 10.1038/s41598-018-24783-4.

7.

Basal ganglia and beyond: The interplay between motor and cognitive aspects in Parkinson's disease rehabilitation.

Ferrazzoli D, Ortelli P, Madeo G, Giladi N, Petzinger GM, Frazzitta G.

Neurosci Biobehav Rev. 2018 Jul;90:294-308. doi: 10.1016/j.neubiorev.2018.05.007. Epub 2018 May 4. Review.

8.

Treadmill walking reduces pre-frontal activation in patients with Parkinson's disease.

Thumm PC, Maidan I, Brozgol M, Shustak S, Gazit E, Shema Shiratzki S, Bernad-Elazari H, Beck Y, Giladi N, Hausdorff JM, Mirelman A.

Gait Posture. 2018 May;62:384-387. doi: 10.1016/j.gaitpost.2018.03.041. Epub 2018 Mar 28.

PMID:
29626840
9.

Application of the Movement Disorder Society prodromal criteria in healthy G2019S-LRRK2 carriers.

Mirelman A, Saunders-Pullman R, Alcalay RN, Shustak S, Thaler A, Gurevich T, Raymond D, Mejia-Santana H, Orbe Reilly M, Ozelius L, Clark L, Gana-Weisz M, Bar-Shira A, Orr-Utreger A, Bressman SB, Marder K, Giladi N; AJ LRRK2 Consortium.

Mov Disord. 2018 Mar 30. doi: 10.1002/mds.27342. [Epub ahead of print]

PMID:
29603409
10.

Evidence for Differential Effects of 2 Forms of Exercise on Prefrontal Plasticity During Walking in Parkinson's Disease.

Maidan I, Nieuwhof F, Bernad-Elazari H, Bloem BR, Giladi N, Hausdorff JM, Claassen JAHR, Mirelman A.

Neurorehabil Neural Repair. 2018 Mar;32(3):200-208. doi: 10.1177/1545968318763750. Epub 2018 Mar 16.

PMID:
29546797
11.

How attention modulates encoding of dynamic stimuli in older adults.

Oren N, Shapira-Lichter I, Lerner Y, Hendler T, Giladi N, Ash EL.

Behav Brain Res. 2018 Jul 16;347:209-218. doi: 10.1016/j.bbr.2018.02.031. Epub 2018 Feb 25.

PMID:
29490234
12.

Effectiveness of a Goal-Based Intensive Rehabilitation in Parkinsonian Patients in Advanced Stages of Disease.

Ortelli P, Ferrazzoli D, Bera R, Caremani L, Giladi N, Maestri R, Frazzitta G.

J Parkinsons Dis. 2018;8(1):113-119. doi: 10.3233/JPD-171247.

PMID:
29480227
13.

Prefrontal cortex activation during obstacle negotiation: What's the effect size and timing?

Maidan I, Shustak S, Sharon T, Bernad-Elazari H, Geffen N, Giladi N, Hausdorff JM, Mirelman A.

Brain Cogn. 2018 Apr;122:45-51. doi: 10.1016/j.bandc.2018.02.006. Epub 2018 Feb 15.

PMID:
29454975
14.

Who will remain tremor dominant? The possible role of cognitive reserve in the time course of two common Parkinson's disease motor subtypes.

Herman T, Shema-Shiratzky S, Arie L, Giladi N, Hausdorff JM.

J Neural Transm (Vienna). 2018 Jun;125(6):1007-1011. doi: 10.1007/s00702-018-1859-3. Epub 2018 Feb 15.

PMID:
29450651
15.

Multitarget transcranial direct current stimulation for freezing of gait in Parkinson's disease.

Dagan M, Herman T, Harrison R, Zhou J, Giladi N, Ruffini G, Manor B, Hausdorff JM.

Mov Disord. 2018 Apr;33(4):642-646. doi: 10.1002/mds.27300. Epub 2018 Feb 13.

16.

Progression in the LRRK2-Asssociated Parkinson Disease Population.

Saunders-Pullman R, Mirelman A, Alcalay RN, Wang C, Ortega RA, Raymond D, Mejia-Santana H, Orbe-Reilly M, Johannes BA, Thaler A, Ozelius L, Orr-Urtreger A, Marder KS, Giladi N, Bressman SB; LRRK2 Ashkenazi Jewish Consortium.

JAMA Neurol. 2018 Mar 1;75(3):312-319. doi: 10.1001/jamaneurol.2017.4019.

PMID:
29309488
17.

Sex differences in LRRK2 G2019S and idiopathic Parkinson's Disease.

San Luciano M, Wang C, Ortega RA, Giladi N, Marder K, Bressman S, Saunders-Pullman R; Michael J Fox Foundation LRRK2 Consortium.

Ann Clin Transl Neurol. 2017 Oct 19;4(11):801-810. doi: 10.1002/acn3.489. eCollection 2017 Nov.

18.

Age-associated changes in obstacle negotiation strategies: Does size and timing matter?

Maidan I, Eyal S, Kurz I, Geffen N, Gazit E, Ravid L, Giladi N, Mirelman A, Hausdorff JM.

Gait Posture. 2018 Jan;59:242-247. doi: 10.1016/j.gaitpost.2017.10.023. Epub 2017 Oct 27.

PMID:
29096267
19.

Medical Cannabis in Parkinson Disease: Real-Life Patients' Experience.

Balash Y, Bar-Lev Schleider L, Korczyn AD, Shabtai H, Knaani J, Rosenberg A, Baruch Y, Djaldetti R, Giladi N, Gurevich T.

Clin Neuropharmacol. 2017 Nov/Dec;40(6):268-272. doi: 10.1097/WNF.0000000000000246.

PMID:
29059132
20.

Validation of the Hebrew version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale.

Zitser J, Peretz C, Ber David A, Shabtai H, Ezra A, Kestenbaum M, Brozgol M, Rosenberg A, Herman T, Balash Y, Gadoth A, Thaler A, Stebbins GT, Goetz CG, Tilley BC, Luo ST, Liu Y, Giladi N, Gurevich T.

Parkinsonism Relat Disord. 2017 Dec;45:7-12. doi: 10.1016/j.parkreldis.2017.09.012. Epub 2017 Sep 24.

21.

Disparate effects of training on brain activation in Parkinson disease.

Maidan I, Rosenberg-Katz K, Jacob Y, Giladi N, Hausdorff JM, Mirelman A.

Neurology. 2017 Oct 24;89(17):1804-1810. doi: 10.1212/WNL.0000000000004576. Epub 2017 Sep 27.

PMID:
28954877
22.

Do cognition and other non-motor symptoms decline similarly among patients with Parkinson's disease motor subtypes? Findings from a 5-year prospective study.

Arie L, Herman T, Shema-Shiratzky S, Giladi N, Hausdorff JM.

J Neurol. 2017 Oct;264(10):2149-2157. doi: 10.1007/s00415-017-8605-x. Epub 2017 Sep 6.

PMID:
28879438
23.

Reduced mind wandering in patients with Parkinson's disease.

Geffen T, Thaler A, Gilam G, Ben Simon E, Sarid N, Gurevich T, Giladi N, Shabtai H, Zitser J, Schilman EA, Sharon H.

Parkinsonism Relat Disord. 2017 Nov;44:38-43. doi: 10.1016/j.parkreldis.2017.08.030. Epub 2017 Sep 1.

PMID:
28877857
24.

Two Ethnic Clusters with Huntington Disease in Israel: The Case of Mountain Jews and Karaites.

Zitser J, Thaler A, Inbar N, Gad A, Faust-Socher A, Paleacu D, Anca-Herschkovitch M, Balash Y, Shabtai H, Ash EL, Merkin L, Manor Y, Kestenbaum M, Bar David A, Peretz C, Naiman T, Bar-Shira A, Orr-Urtreger A, Dangoor N, Giladi N, Gurevich T.

Neurodegener Dis. 2017;17(6):281-285. doi: 10.1159/000479375. Epub 2017 Aug 25.

PMID:
28848105
25.

Schema benefit vs. proactive interference: Contradicting behavioral outcomes and coexisting neural patterns.

Oren N, Shapira-Lichter I, Lerner Y, Tarrasch R, Hendler T, Giladi N, Ash EL.

Neuroimage. 2017 Sep;158:271-281. doi: 10.1016/j.neuroimage.2017.07.006. Epub 2017 Jul 5.

PMID:
28689053
26.

Estimation of genetic risk function with covariates in the presence of missing genotypes.

Lee AJ, Marder K, Alcalay RN, Mejia-Santana H, Orr-Urtreger A, Giladi N, Bressman S, Wang Y.

Stat Med. 2017 Sep 30;36(22):3533-3546. doi: 10.1002/sim.7376. Epub 2017 Jun 27.

PMID:
28656686
27.

Penetrance estimate of LRRK2 p.G2019S mutation in individuals of non-Ashkenazi Jewish ancestry.

Lee AJ, Wang Y, Alcalay RN, Mejia-Santana H, Saunders-Pullman R, Bressman S, Corvol JC, Brice A, Lesage S, Mangone G, Tolosa E, Pont-Sunyer C, Vilas D, Schüle B, Kausar F, Foroud T, Berg D, Brockmann K, Goldwurm S, Siri C, Asselta R, Ruiz-Martinez J, Mondragón E, Marras C, Ghate T, Giladi N, Mirelman A, Marder K; Michael J. Fox LRRK2 Cohort Consortium.

Mov Disord. 2017 Oct;32(10):1432-1438. doi: 10.1002/mds.27059. Epub 2017 Jun 22.

PMID:
28639421
28.

The role of the prefrontal cortex in freezing of gait in Parkinson's disease: insights from a deep repetitive transcranial magnetic stimulation exploratory study.

Dagan M, Herman T, Mirelman A, Giladi N, Hausdorff JM.

Exp Brain Res. 2017 Aug;235(8):2463-2472. doi: 10.1007/s00221-017-4981-9. Epub 2017 May 16.

PMID:
28509934
29.

When is Higher Level Cognitive Control Needed for Locomotor Tasks Among Patients with Parkinson's Disease?

Maidan I, Bernad-Elazari H, Giladi N, Hausdorff JM, Mirelman A.

Brain Topogr. 2017 Jul;30(4):531-538. doi: 10.1007/s10548-017-0564-0. Epub 2017 Apr 24.

PMID:
28439757
30.

Effects of aging on prefrontal brain activation during challenging walking conditions.

Mirelman A, Maidan I, Bernad-Elazari H, Shustack S, Giladi N, Hausdorff JM.

Brain Cogn. 2017 Jul;115:41-46. doi: 10.1016/j.bandc.2017.04.002. Epub 2017 Apr 21.

PMID:
28433922
31.

Focused and Sustained Attention Is Modified by a Goal-Based Rehabilitation in Parkinsonian Patients.

Ferrazzoli D, Ortelli P, Maestri R, Bera R, Gargantini R, Palamara G, Zarucchi M, Giladi N, Frazzitta G.

Front Behav Neurosci. 2017 Mar 31;11:56. doi: 10.3389/fnbeh.2017.00056. eCollection 2017.

32.

DaT-SPECT assessment depicts dopamine depletion among asymptomatic G2019S LRRK2 mutation carriers.

Artzi M, Even-Sapir E, Lerman Shacham H, Thaler A, Urterger AO, Bressman S, Marder K, Hendler T, Giladi N, Ben Bashat D, Mirelman A.

PLoS One. 2017 Apr 13;12(4):e0175424. doi: 10.1371/journal.pone.0175424. eCollection 2017.

33.

Gently does it: Humans outperform a software classifier in recognizing subtle, nonstereotypical facial expressions.

Yitzhak N, Giladi N, Gurevich T, Messinger DS, Prince EB, Martin K, Aviezer H.

Emotion. 2017 Dec;17(8):1187-1198. doi: 10.1037/emo0000287. Epub 2017 Apr 13.

PMID:
28406679
34.

Statin adherence and the risk of Parkinson's disease: A population-based cohort study.

Rozani V, Giladi N, El-Ad B, Gurevich T, Tsamir J, Hemo B, Peretz C.

PLoS One. 2017 Apr 7;12(4):e0175054. doi: 10.1371/journal.pone.0175054. eCollection 2017.

35.

A randomized trial of a low-dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson's disease.

Olanow CW, Kieburtz K, Leinonen M, Elmer L, Giladi N, Hauser RA, Klepiskaya OS, Kreitzman DL, Lew MF, Russell DS, Kadosh S, Litman P, Friedman H, Linvah N, The P B Study Group F.

Mov Disord. 2017 May;32(5):783-789. doi: 10.1002/mds.26941. Epub 2017 Apr 3.

PMID:
28370340
36.

Clinical Practice: Evidence-Based Recommendations for the Treatment of Cervical Dystonia with Botulinum Toxin.

Contarino MF, Van Den Dool J, Balash Y, Bhatia K, Giladi N, Koelman JH, Lokkegaard A, Marti MJ, Postma M, Relja M, Skorvanek M, Speelman JD, Zoons E, Ferreira JJ, Vidailhet M, Albanese A, Tijssen MA.

Front Neurol. 2017 Feb 24;8:35. doi: 10.3389/fneur.2017.00035. eCollection 2017. Review.

37.

Neural patterns underlying the effect of negative distractors on working memory in older adults.

Oren N, Ash EL, Tarrasch R, Hendler T, Giladi N, Shapira-Lichter I.

Neurobiol Aging. 2017 May;53:93-102. doi: 10.1016/j.neurobiolaging.2017.01.020. Epub 2017 Feb 3.

PMID:
28242539
38.

Subthalamic Neurons Encode Both Single- and Multi-Limb Movements in Parkinson's Disease Patients.

Tankus A, Strauss I, Gurevich T, Mirelman A, Giladi N, Fried I, Hausdorff JM.

Sci Rep. 2017 Feb 13;7:42467. doi: 10.1038/srep42467.

39.

A "dose" effect of mutations in the GBA gene on Parkinson's disease phenotype.

Thaler A, Gurevich T, Bar Shira A, Gana Weisz M, Ash E, Shiner T, Orr-Urtreger A, Giladi N, Mirelman A.

Parkinsonism Relat Disord. 2017 Mar;36:47-51. doi: 10.1016/j.parkreldis.2016.12.014. Epub 2016 Dec 16.

PMID:
28012950
40.

The clinical significance of freezing while turning in Parkinson's disease.

Mancini M, Smulders K, Cohen RG, Horak FB, Giladi N, Nutt JG.

Neuroscience. 2017 Feb 20;343:222-228. doi: 10.1016/j.neuroscience.2016.11.045. Epub 2016 Dec 9.

41.

How Attention Modulates Encoding of Dynamic Stimuli.

Oren N, Shapira-Lichter I, Lerner Y, Tarrasch R, Hendler T, Giladi N, Ash EL.

Front Hum Neurosci. 2016 Oct 21;10:507. eCollection 2016.

42.

Neuropsychiatric characteristics of GBA-associated Parkinson disease.

Swan M, Doan N, Ortega RA, Barrett M, Nichols W, Ozelius L, Soto-Valencia J, Boschung S, Deik A, Sarva H, Cabassa J, Johannes B, Raymond D, Marder K, Giladi N, Miravite J, Severt W, Sachdev R, Shanker V, Bressman S, Saunders-Pullman R.

J Neurol Sci. 2016 Nov 15;370:63-69. doi: 10.1016/j.jns.2016.08.059. Epub 2016 Aug 30.

43.

Efficacy of Rotigotine at Different Stages of Parkinson's Disease Symptom Severity and Disability: A Post Hoc Analysis According to Baseline Hoehn and Yahr Stage.

Giladi N, Nicholas AP, Asgharnejad M, Dohin E, Woltering F, Bauer L, Poewe W.

J Parkinsons Dis. 2016 Oct 19;6(4):741-749.

44.

High Frequency of GBA Gene Mutations in Dementia With Lewy Bodies Among Ashkenazi Jews.

Shiner T, Mirelman A, Gana Weisz M, Bar-Shira A, Ash E, Cialic R, Nevler N, Gurevich T, Bregman N, Orr-Urtreger A, Giladi N.

JAMA Neurol. 2016 Dec 1;73(12):1448-1453. doi: 10.1001/jamaneurol.2016.1593.

PMID:
27723861
45.

Transition Between the Timed up and Go Turn to Sit Subtasks: Is Timing Everything?

Weiss A, Mirelman A, Giladi N, Barnes LL, Bennett DA, Buchman AS, Hausdorff JM.

J Am Med Dir Assoc. 2016 Sep 1;17(9):864.e9-864.e15. doi: 10.1016/j.jamda.2016.06.025.

46.

Does Cognitive Impairment Affect Rehabilitation Outcome in Parkinson's Disease?

Ferrazzoli D, Ortelli P, Maestri R, Bera R, Giladi N, Ghilardi MF, Pezzoli G, Frazzitta G.

Front Aging Neurosci. 2016 Aug 11;8:192. doi: 10.3389/fnagi.2016.00192. eCollection 2016.

47.

Can a single lower trunk body-fixed sensor differentiate between level-walking and stair descent and ascent in older adults? Preliminary findings.

Weiss A, Brozgol M, Giladi N, Hausdorff JM.

Med Eng Phys. 2016 Oct;38(10):1146-51. doi: 10.1016/j.medengphy.2016.07.008. Epub 2016 Aug 12.

PMID:
27527394
48.

Addition of a non-immersive virtual reality component to treadmill training to reduce fall risk in older adults (V-TIME): a randomised controlled trial.

Mirelman A, Rochester L, Maidan I, Del Din S, Alcock L, Nieuwhof F, Rikkert MO, Bloem BR, Pelosin E, Avanzino L, Abbruzzese G, Dockx K, Bekkers E, Giladi N, Nieuwboer A, Hausdorff JM.

Lancet. 2016 Sep 17;388(10050):1170-82. doi: 10.1016/S0140-6736(16)31325-3. Epub 2016 Aug 11.

PMID:
27524393
49.

Subcortical Volumes Differ in Parkinson's Disease Motor Subtypes: New Insights into the Pathophysiology of Disparate Symptoms.

Rosenberg-Katz K, Herman T, Jacob Y, Kliper E, Giladi N, Hausdorff JM.

Front Hum Neurosci. 2016 Jul 11;10:356. doi: 10.3389/fnhum.2016.00356. eCollection 2016.

50.

Alterations in conflict monitoring are related to functional connectivity in Parkinson's disease.

Rosenberg-Katz K, Maidan I, Jacob Y, Giladi N, Mirelman A, Hausdorff JM.

Cortex. 2016 Sep;82:277-286. doi: 10.1016/j.cortex.2016.06.014. Epub 2016 Jun 25.

PMID:
27453508

Supplemental Content

Loading ...
Support Center